Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IFCT-2502 LIMPID
2025-522790-10-00Phase 2Authorised
- Sponsor
- IFCT
- Start
- Sep 2026
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of bevacizumab, pembrolizumab, vinorelbine, gemcitabine, nivolumab and 3 more in non-small cell lung cancer (NSCLC) and interstitial lung disease (ILD) (2 arms), sponsored by IFCT. Primary endpoints: Disease control rate at 8 weeks (first-line) and Treatment-related respiratory worsening leading to discontinuation (second-line). Planned start Sep 2026; status: authorised.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)interstitial lung disease (ILD)
Beyond the preview
Go deeper on 2025-522790-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522790-10-00.